X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

As Per WHO Omicron To Affect Above 50% of Europe In 2 Months

Content Team by Content Team
17th January 2022
in News
As Per WHO Omicron To Affect Above 50% of Europe In 2 Months

According to the forecast shared by WHO top officials more than half of Europe will suffer from the highly contagious variant of COVID-19, Omicron in the next couple of months. As per one of the top line directors at WHO, there is a sweep of the west to east tidal wave of infection of Omicron which in the region over and above the pre-existent delta variant.

The variant is dominantly stamping its spread across the west of Europe and is now charging towards the Balkans. The region has already seen above 7 million patients in the first week of this year. This figure is double to the two-week prior period. With the rate things are moving, the health metrics and evaluation institute predict that more than half of the regional population will be under the clutches of omicron and that too in the next 6-8 weeks.

The variant has swept the entire region at a brisk pace and countries, big or small, developed or developing are already introducing various social restrictions to curb its unwanted expanse. All the shreds of evidence however suggest that the omicron is less lethal than the delta variant but the sheer numbers are enough to overwhelm the health care system. One of the professors at Oxford believes that omicron is not the same virus as its predecessors and the horrific scenes that all had to go through of people succumbing prematurely, hospitals overflowing with admissions is history.

As far as the disease is concerned, the variant seems to be less impactful with many people being hospitalized for a less period of time. Oxygen high flow isn’t the need with an average stay of patients being three days max. The fact is that the places where COVID incident rates have been higher tagged with low vaccination turnouts, the mortality rate is stable.

Previous Post

Eagle Genomics and Quadram Institute's New Strategic Partnership to Accelerate Microbiome Analysis Through AI-Augmented Knowledge Discovery Platform

Next Post

Ensovibep Therepeutic Candidate To Fight COVID-19 Makes Way

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Next Post
Ensovibep Therepeutic Candidate To Fight COVID-19 Makes Way

Ensovibep Therepeutic Candidate To Fight COVID-19 Makes Way

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In